MARKET OUTLOOK The hospital-treated gram-negative infection (GNI) therapy market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-…
MARKET OUTLOOK The hospital-treated gram-negative infection (GNI) therapy market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-…
Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disease characterized by progressive chorea, dystonia, and cognitive decline. Current treatment is entirely focused on…
MARKET OUTLOOK The increase in oral oncolytics has fueled an increase in physician dispensing of drugs either from the office or from a pharmacy owned by the practice or hospital, as allowed by…
Market Outlook The most important clinical distinction in the first-line treatment of multiple myeloma is determining whether the patient is eligible to undergo autologous stem-cell…
Market Outlook The most important clinical distinction in the first-line treatment of multiple myeloma is determining whether the patient is eligible to undergo autologous stem-cell…
MARKET OUTLOOK Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…
MARKET OUTLOOK Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…
MARKET OUTLOOK Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…
Acute myeloid leukemia (AML) is the most common and aggressive form of leukemia in adults, with the lowest survival rates of all blood cancer types. Despite significant advances in understanding…
MARKET OUTLOOK Acute myeloid leukemia (AML) is the most common and aggressive form of leukemia in adults, with the lowest survival rates of all blood cancer types. Despite significant advances in…
MARKET OUTLOOK Obesity is arguably the most pressing public health issue in the United States. The prevalence of obesity is extremely high, and its chronic progression is associated with type 2…
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only oral targeted therapy approved for this indication besides Celgene’s PDE-4…
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only oral targeted therapy approved for this indication besides Celgene’s PDE-4…
Market Outlook The U.S. treatment landscape for osteoarthritic (OA) pain, despite being highly genericized, contains a large number of brand-only agents, including multiple opioid analgesics with…